Comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 vs 16p12 1p12 3 Triplication Syndrome C5680097
Clinical comparison between 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia and 16p12 1p12 3 Triplication Syndrome for differential diagnosis and treatment planning.
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
An inherited disorder affecting adrenal hormone production, causing cortisol deficiency and other hormonal imbalances. Features may include ambiguous genitalia, salt-wasting crises, and growth issues. Treated with lifelong hormone replacement therapy.
16p12 1p12 3 Triplication Syndrome C5680097
An extremely rare chromosomal disorder involving three copies of genetic material on chromosome 16. Limited cases are reported, and features may include developmental delays and physical differences. Care is individualized based on specific needs.
6 comparison axes
Onset
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
0-null
16p12 1p12 3 Triplication Syndrome C5680097
0-null
Onset patterns differ
Severity
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
severe
16p12 1p12 3 Triplication Syndrome C5680097
moderate
Different severity levels
Chronic
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
Chronic
16p12 1p12 3 Triplication Syndrome C5680097
Chronic
Differing course
Communicable
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
No
16p12 1p12 3 Triplication Syndrome C5680097
No
Different transmission
Body System
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
16p12 1p12 3 Triplication Syndrome C5680097
congenital
Same/different system
Category
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
16p12 1p12 3 Triplication Syndrome C5680097
genetic
Different category
Bottom line
21-hydroxylase-deficient-congenital-adrenal-hyperplasia-C2936858 and 16p12-1p12-3-triplication-syndrome-C5680097 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 16p12 1p12 3 Triplication Syndrome C5680097 | Discriminating power |
|---|---|---|---|
| Hormone imbalance | Cortisol deficiency with possible androgen excess and salt wasting | Not primarily adrenal; characteristic hormone pattern is not established | High |
| Development | Growth issues may occur; neurodevelopment is not defining | Developmental delay may be reported, but the spectrum is poorly defined | Moderate |
| Physical findings | Ambiguous genitalia may occur in affected infants | Physical differences may occur; specific features are not established | Moderate |
When to favor each condition
Choose 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 when
Suspected adrenal crisis or atypical genitalia
Fits cortisol deficiency and possible salt wasting better than a chromosomal diagnosis
High
Newborn screening suggests CAH
Needs endocrine confirmation rather than assuming a chromosome disorder
High
Recessive adrenal-disorder family history
Supports targeted CYP21A2-related evaluation
Moderate
Choose 16p12 1p12 3 Triplication Syndrome C5680097 when
Developmental delay with congenital differences
Chromosomal testing may be considered; this triplication is extremely rare
Moderate
Testing shows extra 16p12.1–p12.3 material
Diagnosis requires laboratory confirmation and clinical correlation
High
No adrenal abnormality but congenital anomalies
A chromosomal condition is more consistent than CAH
Moderate
How key tests differ
| Test | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 16p12 1p12 3 Triplication Syndrome C5680097 | Interpretation |
|---|---|---|---|
| Adrenal steroid profile | May show a pattern consistent with 21-hydroxylase deficiency | Not expected to establish this chromosomal condition | Steroid abnormalities support CAH but need clinician and assay context |
| Serum electrolytes | Salt wasting may cause low sodium and high potassium | No characteristic electrolyte pattern is established | Changes can be urgent but are not diagnostic alone |
| Genetic testing | CYP21A2-related testing can support the diagnosis | Microarray or equivalent can detect the triplication | The tests assess different genetic mechanisms |
Prognosis comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
- Outcome
- Chronic condition often managed with hormone replacement; outcomes vary
- Factors
- Salt-wasting risk, illness management, and treatment adherence
16p12 1p12 3 Triplication Syndrome C5680097
- Outcome
- Prognosis is not established because reported cases are extremely limited
- Factors
- Individual developmental, medical, and support needs
Time frame: Lifelong, with early childhood often clinically important
Confirmed diagnosis, specialist follow-up, and family support
Complications comparison
| Complication | Presentation |
|---|---|
| Adrenal crisis | Possible, especially with illness or salt wasting Not an established feature Vomiting, lethargy, or dehydration in suspected CAH needs urgent care |
| Growth and puberty effects | May result from hormone imbalance or treatment Growth effects are not well characterized Course and monitoring should be individualized |
| Developmental needs | Not the primary complication Delay may require educational or developmental support Published evidence for the triplication is limited |
Patient education highlights
- HighEmergency recognition
For suspected CAH, use an illness plan and seek urgent care for crisis symptoms.
- HighGenetic counseling
Both have genetic implications; specialists should interpret results and recurrence risk.
- MediumFollow-up
CAH generally needs lifelong endocrine care; the chromosomal condition needs individualized support.